PharmaResearch Co., Ltd.

KOSDAQ:A214450 Stock Report

Market Cap: ₩2.8t

PharmaResearch Balance Sheet Health

Financial Health criteria checks 6/6

PharmaResearch has a total shareholder equity of ₩543.0B and total debt of ₩28.5B, which brings its debt-to-equity ratio to 5.2%. Its total assets and total liabilities are ₩640.8B and ₩97.8B respectively. PharmaResearch's EBIT is ₩112.7B making its interest coverage ratio -16.4. It has cash and short-term investments of ₩216.4B.

Key information

5.2%

Debt to equity ratio

₩28.47b

Debt

Interest coverage ratio-16.4x
Cash₩216.41b
Equity₩543.03b
Total liabilities₩97.78b
Total assets₩640.82b

Recent financial health updates

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Mar 23
Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Dec 08
Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Recent updates

What PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 32% Share Price Gain Is Not Telling You

Dec 19
What PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 32% Share Price Gain Is Not Telling You

PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Aug 15
PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today

May 21
Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Apr 09
PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Mar 23
Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Mar 05
Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Feb 17
Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

Feb 02
Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

Jan 20
Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Jan 07
Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

Dec 23
Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Dec 08
Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Nov 25
Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Financial Position Analysis

Short Term Liabilities: A214450's short term assets (₩337.7B) exceed its short term liabilities (₩83.4B).

Long Term Liabilities: A214450's short term assets (₩337.7B) exceed its long term liabilities (₩14.4B).

Debt to Equity History and Analysis

Debt Level: A214450 has more cash than its total debt.

Reducing Debt: A214450's debt to equity ratio has reduced from 8.6% to 5.2% over the past 5 years.

Debt Coverage: A214450's debt is well covered by operating cash flow (429.4%).

Interest Coverage: A214450 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 10:48
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaResearch Co., Ltd. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sae-rom LeeDaishin Securities Co. Ltd.
Jonghyun ParkDAOL Investment & Securities Co., Ltd.
Tae-Na JoEugene Investment & Securities Co Ltd.